GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » INmune Bio Inc (NAS:INMB) » Definitions » EPS without NRI

INmune Bio (INmune Bio) EPS without NRI : $-1.67 (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is INmune Bio EPS without NRI?

INmune Bio's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $-0.47. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.67.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -18.20% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -12.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for INmune Bio's EPS without NRI or its related term are showing as below:

INMB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -255.7   Med: -19.2   Max: -18.2
Current: -18.2

During the past 8 years, INmune Bio's highest 3-Year average Earnings Per Share (NRI) Growth Rate was -18.20% per year. The lowest was -255.70% per year. And the median was -19.20% per year.

INMB's 3-Year EPS without NRI Growth Rate is ranked worse than
74.15% of 1296 companies
in the Biotechnology industry
Industry Median: 4.8 vs INMB: -18.20

INmune Bio's EPS (Diluted) for the three months ended in Dec. 2023 was $-0.47. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.67.

INmune Bio's EPS (Basic) for the three months ended in Dec. 2023 was $-0.47. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.67.


INmune Bio EPS without NRI Historical Data

The historical data trend for INmune Bio's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

INmune Bio EPS without NRI Chart

INmune Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial -0.90 -1.01 -1.88 -1.52 -1.67

INmune Bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.32 -0.36 -0.36 -0.48 -0.47

Competitive Comparison of INmune Bio's EPS without NRI

For the Biotechnology subindustry, INmune Bio's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


INmune Bio's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, INmune Bio's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where INmune Bio's PE Ratio without NRI falls into.



INmune Bio EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


INmune Bio  (NAS:INMB) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


INmune Bio EPS without NRI Related Terms

Thank you for viewing the detailed overview of INmune Bio's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


INmune Bio (INmune Bio) Business Description

Traded in Other Exchanges
N/A
Address
225 NE Mizner Boulevard, Suite 640, Boca Raton, FL, USA, 33432
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
Executives
Scott Juda director 325 N. LARCHMONT BLVD, SUITE 375, LOS ANGELES CA 90004
Timothy J Schroeder director 2690 DEVILS BACKBONE ROAD, CINCINNATI OH 45233
David J Moss 10 percent owner, officer: CFO, Treasurer & Secretary C/O PEGASI ENERGY RESOURCES CORPORATION, 218 N. BROADWAY, SUITE 204, TYLER TX 75702
Raymond Joseph Tesi director, 10 percent owner, officer: President & CEO 476 MASSACHUSETTS AVE, UNIT 2, BOSTON MA 02118
Mark William Lowdell 10 percent owner, officer: Chief Scientific Officer THE OAK, WLX ROAD, BEAUMONT X0 CO16 0AT
Linda F Powers 10 percent owner 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
James Kelly Ganjei director 10609 RIVER OAKS LANE, POTOMAC MD 20859
Marcia Allen director P.O. BOX 399, 2600 W. HOMESTEAD CIRCLE, WILSON WY 83014
Edgardo Jr Baracchini director C/O METABASIS THERAPEUTICS, 9390 TOWNE CENTRE DRIVE, BLDG. 300, SAN DIEGO CA 92121
Xencor Inc 10 percent owner 465 N. HALSTEAD ST., SUITE 200, PASADENA CA 91107
David Edmund Szymkowski director 241 WEST PALM AVENUE, MONROVIA CA 91016

INmune Bio (INmune Bio) Headlines

From GuruFocus

INmune Bio Inc (INMB) Reports Q3 2023 Financial Results

By GuruFocus Research 11-01-2023